Novel antiviral activity of bromocriptine against dengue virus replication

Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed vaccines or specific antiviral drugs against this infection are not available. To identify novel anti-DENV compounds, we screened 1280 pharmacologically active compounds using focus reduction assay....

Full description

Saved in:
Bibliographic Details
Published inAntiviral research Vol. 131; pp. 141 - 147
Main Authors Kato, Fumihiro, Ishida, Yuki, Oishi, Shinya, Fujii, Nobutaka, Watanabe, Satoru, Vasudevan, Subhash G., Tajima, Shigeru, Takasaki, Tomohiko, Suzuki, Youichi, Ichiyama, Koji, Yamamoto, Naoki, Yoshii, Kentaro, Takashima, Ikuo, Kobayashi, Takeshi, Miura, Tomoyuki, Igarashi, Tatsuhiko, Hishiki, Takayuki
Format Journal Article
LanguageEnglish
Published Netherlands 01.07.2016
Subjects
Antiviral Agents - pharmacology
Bromocriptine - pharmacology
Dengue - drug therapy
Dengue virus
Dengue Virus - drug effects
Dengue Virus - physiology
Drug Resistance, Viral
Humans
Replicon - drug effects
Viral Plaque Assay
Virus Replication - drug effects
Time-of-drug addition
Focus assay
Antiviral drug
Dengue virus
Bromocriptine
Replicon
Online AccessGet full text

Cover

Abstract Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed vaccines or specific antiviral drugs against this infection are not available. To identify novel anti-DENV compounds, we screened 1280 pharmacologically active compounds using focus reduction assay. Bromocriptine (BRC) was found to have potent anti-DENV activity and low cytotoxicity (half maximal effective concentration [EC50], 0.8-1.6 μM; and half maximal cytotoxicity concentration [CC50], 53.6 μM). Time-of-drug-addition and time-of-drug-elimination assays suggested that BRC inhibits translation and/or replication steps in the DENV life cycle. A subgenomic replicon system was used to verify that BRC restricts RNA replication step. Furthermore, a single amino acid substitution (N374H) was detected in the NS3 protein that conferred resistance to BRC. In summary, BRC was found to be a novel DENV inhibitor and a potential candidate for the treatment of DENV infectious disease.
AbstractList Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed vaccines or specific antiviral drugs against this infection are not available. To identify novel anti-DENV compounds, we screened 1280 pharmacologically active compounds using focus reduction assay. Bromocriptine (BRC) was found to have potent anti-DENV activity and low cytotoxicity (half maximal effective concentration [EC50], 0.8-1.6 mu M; and half maximal cytotoxicity concentration [CC50], 53.6 mu M). Time-of-drug-addition and time-of-drug-elimination assays suggested that BRC inhibits translation and/or replication steps in the DENV life cycle. A subgenomic replicon system was used to verify that BRC restricts RNA replication step. Furthermore, a single amino acid substitution (N374H) was detected in the NS3 protein that conferred resistance to BRC. In summary, BRC was found to be a novel DENV inhibitor and a potential candidate for the treatment of DENV infectious disease.
Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed vaccines or specific antiviral drugs against this infection are not available. To identify novel anti-DENV compounds, we screened 1280 pharmacologically active compounds using focus reduction assay. Bromocriptine (BRC) was found to have potent anti-DENV activity and low cytotoxicity (half maximal effective concentration [EC50], 0.8-1.6 μM; and half maximal cytotoxicity concentration [CC50], 53.6 μM). Time-of-drug-addition and time-of-drug-elimination assays suggested that BRC inhibits translation and/or replication steps in the DENV life cycle. A subgenomic replicon system was used to verify that BRC restricts RNA replication step. Furthermore, a single amino acid substitution (N374H) was detected in the NS3 protein that conferred resistance to BRC. In summary, BRC was found to be a novel DENV inhibitor and a potential candidate for the treatment of DENV infectious disease.
Author Yamamoto, Naoki
Yoshii, Kentaro
Hishiki, Takayuki
Fujii, Nobutaka
Takashima, Ikuo
Vasudevan, Subhash G.
Oishi, Shinya
Miura, Tomoyuki
Kobayashi, Takeshi
Ichiyama, Koji
Watanabe, Satoru
Igarashi, Tatsuhiko
Ishida, Yuki
Tajima, Shigeru
Kato, Fumihiro
Suzuki, Youichi
Takasaki, Tomohiko
Author_xml – sequence: 1
  givenname: Fumihiro
  surname: Kato
  fullname: Kato, Fumihiro
– sequence: 2
  givenname: Yuki
  surname: Ishida
  fullname: Ishida, Yuki
– sequence: 3
  givenname: Shinya
  surname: Oishi
  fullname: Oishi, Shinya
– sequence: 4
  givenname: Nobutaka
  surname: Fujii
  fullname: Fujii, Nobutaka
– sequence: 5
  givenname: Satoru
  surname: Watanabe
  fullname: Watanabe, Satoru
– sequence: 6
  givenname: Subhash G.
  surname: Vasudevan
  fullname: Vasudevan, Subhash G.
– sequence: 7
  givenname: Shigeru
  surname: Tajima
  fullname: Tajima, Shigeru
– sequence: 8
  givenname: Tomohiko
  orcidid: 0000-0002-7245-0516
  surname: Takasaki
  fullname: Takasaki, Tomohiko
– sequence: 9
  givenname: Youichi
  surname: Suzuki
  fullname: Suzuki, Youichi
– sequence: 10
  givenname: Koji
  surname: Ichiyama
  fullname: Ichiyama, Koji
– sequence: 11
  givenname: Naoki
  surname: Yamamoto
  fullname: Yamamoto, Naoki
– sequence: 12
  givenname: Kentaro
  surname: Yoshii
  fullname: Yoshii, Kentaro
– sequence: 13
  givenname: Ikuo
  surname: Takashima
  fullname: Takashima, Ikuo
– sequence: 14
  givenname: Takeshi
  surname: Kobayashi
  fullname: Kobayashi, Takeshi
– sequence: 15
  givenname: Tomoyuki
  surname: Miura
  fullname: Miura, Tomoyuki
– sequence: 16
  givenname: Tatsuhiko
  surname: Igarashi
  fullname: Igarashi, Tatsuhiko
– sequence: 17
  givenname: Takayuki
  orcidid: 0000-0001-6581-3668
  surname: Hishiki
  fullname: Hishiki, Takayuki
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27181378$$D View this record in MEDLINE/PubMed
BookMark eNqFkMtOwzAQRS1URB_wC5AlmwQ7dmxnwQJVPFXBBtaW49qVqyQOtlOpf09KHws2rGY0c-6M7p2CUetaDcANghmCiN6tM9lGu7Fe1lk-DDJIMojIGZggzvK0hCUdgcmwoCkuSD4G0xDWEELKSn4BxjlDHGHGJ-Dt3W10nZyuJVLturhNnEkq7xqnvO2ibXUiV9K2ISZL3a56nQx4HxKvu9oqGa1rL8G5kXXQV4c6A19Pj5_zl3Tx8fw6f1ikilAUU5YbBiXmBBGqKOa4zDnBFa-IxJQuMcOmNMRUikPFc0UpKjA3khcYG6RZhWfgdn-38-671yGKxgal61q22vVBIA45xYTkxYBeH9C-avRSdN420m_F0f8A3O8B5V0IXhuhbPx1E720tUBQ7PIWa3FKSOzyFpCIIe9Bz_7ojy_-U_4Av8OJWw
CitedBy_id crossref_primary_10_2174_0929867327666200812215852
crossref_primary_10_3382_ps_pey255
crossref_primary_10_3389_fmicb_2017_01674
crossref_primary_10_1002_ptr_6917
crossref_primary_10_1038_s44298_024_00031_7
crossref_primary_10_1016_j_virusres_2023_199062
crossref_primary_10_1016_j_psj_2019_11_060
crossref_primary_10_1080_1062936X_2024_2392677
crossref_primary_10_1111_1440_1681_13678
crossref_primary_10_3390_applmicrobiol2040059
crossref_primary_10_1016_j_virol_2020_09_004
crossref_primary_10_3390_molecules27144566
crossref_primary_10_1038_s41598_018_21582_9
crossref_primary_10_1080_07391102_2020_1811773
crossref_primary_10_1371_journal_ppat_1009788
crossref_primary_10_3390_microorganisms11102427
crossref_primary_10_1080_07391102_2020_1802346
crossref_primary_10_3390_v17010074
crossref_primary_10_1016_j_jpha_2020_08_002
crossref_primary_10_3390_tropicalmed5030114
crossref_primary_10_1248_cpb_c17_00794
crossref_primary_10_1002_jmv_27386
crossref_primary_10_1016_j_ejmech_2019_05_010
crossref_primary_10_1016_j_antiviral_2019_03_002
crossref_primary_10_5454_mi_13_1_1
crossref_primary_10_1016_j_coviro_2019_01_005
crossref_primary_10_1016_j_antiviral_2017_02_002
crossref_primary_10_3390_v14102150
crossref_primary_10_1080_15476286_2023_2264003
crossref_primary_10_1186_s12985_024_02487_8
crossref_primary_10_1021_acsmedchemlett_0c00042
crossref_primary_10_1038_nrd_2017_33
crossref_primary_10_3390_v15030705
crossref_primary_10_3389_fmicb_2020_00725
crossref_primary_10_1080_03639045_2024_2449130
crossref_primary_10_1016_j_ejphar_2017_12_029
crossref_primary_10_1038_srep41864
crossref_primary_10_2217_fmb_2021_0002
crossref_primary_10_1016_j_antiviral_2019_03_011
crossref_primary_10_1080_07391102_2021_1977698
crossref_primary_10_1016_j_cellsig_2018_05_002
crossref_primary_10_1038_s41401_019_0316_7
crossref_primary_10_1016_j_aichem_2023_100014
crossref_primary_10_3390_v12091022
crossref_primary_10_3390_v10050255
crossref_primary_10_1007_s40506_018_0160_1
crossref_primary_10_2174_1871526520999200905122052
crossref_primary_10_1002_prot_26164
crossref_primary_10_1016_j_carbpol_2018_06_039
crossref_primary_10_1128_AAC_01943_17
crossref_primary_10_1016_j_jpba_2017_11_064
crossref_primary_10_1111_1348_0421_12828
crossref_primary_10_1016_j_jep_2023_116436
crossref_primary_10_1016_j_coviro_2020_07_009
crossref_primary_10_1021_acsinfecdis_8b00054
crossref_primary_10_1016_j_antiviral_2019_104643
crossref_primary_10_1016_j_antiviral_2023_105607
crossref_primary_10_61186_phypha_28_4_363
crossref_primary_10_1016_j_bioorg_2021_105494
crossref_primary_10_1042_BSR20240134
crossref_primary_10_1016_j_antiviral_2017_07_007
crossref_primary_10_1016_j_biochi_2019_05_004
crossref_primary_10_1038_s41598_022_20284_7
crossref_primary_10_1016_j_tet_2025_134468
crossref_primary_10_1007_s40203_021_00089_8
Cites_doi 10.1016/j.antiviral.2009.12.011
10.1128/JVI.71.5.3466-3473.1997
10.1016/j.antiviral.2013.09.013
10.1016/j.antiviral.2013.05.011
10.1371/journal.ppat.1002934
10.1016/j.antiviral.2015.08.013
10.1128/AAC.01281-13
10.1097/00045391-199801000-00007
10.1074/jbc.M114.607341
10.1016/j.antiviral.2012.09.023
10.1099/vir.0.031229-0
10.7883/yoken.67.209
10.1128/AAC.00189-09
10.1099/vir.0.81844-0
10.1016/S0006-8993(99)01812-0
10.1128/AAC.00620-11
10.1111/j.1708-8305.2007.00130.x
10.1111/j.1471-4159.2012.07956.x
10.1128/JCM.35.8.1943-1947.1997
10.1073/pnas.1010811107
10.1056/NEJMra1110265
10.1016/S0014-2999(98)00896-6
10.1007/s00210-008-0341-4
10.1146/annurev.mi.44.100190.003245
10.1016/j.antiviral.2012.07.008
10.1074/jbc.M110.214189
10.1016/j.antiviral.2011.05.001
10.1074/jbc.270.32.19100
10.1016/j.virusres.2005.08.015
10.1128/CMR.11.3.480
10.1128/JVI.00855-15
10.1016/S0026-0495(99)90202-0
10.1016/j.theriogenology.2012.08.003
10.1016/j.antiviral.2015.03.014
10.1128/JVI.03454-14
10.1074/mcp.M111.012187
ContentType Journal Article
Copyright Copyright © 2016 The Author(s). Published by Elsevier B.V. All rights reserved.
Copyright_xml – notice: Copyright © 2016 The Author(s). Published by Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T2
7T7
7U9
8FD
C1K
FR3
H94
P64
DOI 10.1016/j.antiviral.2016.04.014
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Health and Safety Science Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList Virology and AIDS Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1872-9096
EndPage 147
ExternalDocumentID 27181378
10_1016_j_antiviral_2016_04_014
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
23M
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AAAJQ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
AAYXX
ABBQC
ABFNM
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ABZDS
ACDAQ
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AFFNX
AFJKZ
AFPUW
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGQPQ
AGRNS
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
C45
CITATION
CJTIS
CNWQP
CS3
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMG
HVGLF
HZ~
IHE
J1W
KOM
LUGTX
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSH
SSI
SSP
SSZ
T5K
TEORI
WUQ
ZGI
ZXP
~G-
AACTN
AFKWA
AJOXV
AMFUW
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T2
7T7
7U9
8FD
C1K
FR3
H94
P64
ID FETCH-LOGICAL-c461t-72f70a384146c638392843b8b4a366d373f9f4fbc80c82c661538fa8533f1e7b3
ISSN 0166-3542
IngestDate Fri Jul 11 04:36:18 EDT 2025
Wed Feb 19 02:41:32 EST 2025
Tue Jul 01 01:32:06 EDT 2025
Thu Apr 24 22:50:56 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Time-of-drug addition
Focus assay
Antiviral drug
Dengue virus
Bromocriptine
Replicon
Language English
License Copyright © 2016 The Author(s). Published by Elsevier B.V. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c461t-72f70a384146c638392843b8b4a366d373f9f4fbc80c82c661538fa8533f1e7b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-7245-0516
0000-0001-6581-3668
OpenAccessLink https://doi.org/10.1016/j.antiviral.2016.04.014
PMID 27181378
PQID 1808634425
PQPubID 23462
PageCount 7
ParticipantIDs proquest_miscellaneous_1808634425
pubmed_primary_27181378
crossref_citationtrail_10_1016_j_antiviral_2016_04_014
crossref_primary_10_1016_j_antiviral_2016_04_014
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-07-00
20160701
PublicationDateYYYYMMDD 2016-07-01
PublicationDate_xml – month: 07
  year: 2016
  text: 2016-07-00
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Antiviral research
PublicationTitleAlternate Antiviral Res
PublicationYear 2016
References Zhang (10.1016/j.antiviral.2016.04.014_bib36) 1999; 48
Heaton (10.1016/j.antiviral.2016.04.014_bib9) 2010; 107
WHO (10.1016/j.antiviral.2016.04.014_bib34) 2013
Qing (10.1016/j.antiviral.2016.04.014_bib20) 2009; 53
Perachon (10.1016/j.antiviral.2016.04.014_bib19) 1999; 366
Zou (10.1016/j.antiviral.2016.04.014_bib37) 2011; 286
Kapoor (10.1016/j.antiviral.2016.04.014_bib11) 1995; 270
Scheller (10.1016/j.antiviral.2016.04.014_bib22) 2009; 379
Tay (10.1016/j.antiviral.2016.04.014_bib27) 2015; 290
Lindenbach (10.1016/j.antiviral.2016.04.014_bib15) 2007
Chan (10.1016/j.antiviral.2016.04.014_bib3) 2015; 123
Takashima (10.1016/j.antiviral.2016.04.014_bib26) 1997; 35
Chambers (10.1016/j.antiviral.2016.04.014_bib2) 1990; 44
Ginther (10.1016/j.antiviral.2016.04.014_bib7) 2012; 78
Zou (10.1016/j.antiviral.2016.04.014_bib38) 2011; 91
Simmons (10.1016/j.antiviral.2016.04.014_bib23) 2012; 366
van Cleef (10.1016/j.antiviral.2016.04.014_bib29) 2013; 99
Chen (10.1016/j.antiviral.2016.04.014_bib4) 1997; 71
Tajima (10.1016/j.antiviral.2016.04.014_bib24) 2006; 116
Reed (10.1016/j.antiviral.2016.04.014_bib21) 1938; 27
Umareddy (10.1016/j.antiviral.2016.04.014_bib28) 2006; 87
Yang (10.1016/j.antiviral.2016.04.014_bib35) 2014; 58
Gubler (10.1016/j.antiviral.2016.04.014_bib8) 1998; 11
Zou (10.1016/j.antiviral.2016.04.014_bib39) 2015; 89
Khadka (10.1016/j.antiviral.2016.04.014_bib13) 2011; 10
Aguirre (10.1016/j.antiviral.2016.04.014_bib1) 2012; 8
Takahashi (10.1016/j.antiviral.2016.04.014_bib25) 2012; 96
Lim (10.1016/j.antiviral.2016.04.014_bib14) 2013; 100
Wang (10.1016/j.antiviral.2016.04.014_bib32) 2011; 55
Luo (10.1016/j.antiviral.2016.04.014_bib16) 2015; 118
Omatsu (10.1016/j.antiviral.2016.04.014_bib18) 2011; 92
Noble (10.1016/j.antiviral.2016.04.014_bib17) 2010; 85
Geurts (10.1016/j.antiviral.2016.04.014_bib6) 1999; 841
Ito (10.1016/j.antiviral.2016.04.014_bib10) 2007; 14
Watanabe (10.1016/j.antiviral.2016.04.014_bib33) 2012; 96
Fernandez-Duenas (10.1016/j.antiviral.2016.04.014_bib5) 2012; 123
Velasco (10.1016/j.antiviral.2016.04.014_bib30) 1998; 5
Kato (10.1016/j.antiviral.2016.04.014_bib12) 2014; 67
Wang (10.1016/j.antiviral.2016.04.014_bib31) 2015; 89
References_xml – volume: 85
  start-page: 450
  year: 2010
  ident: 10.1016/j.antiviral.2016.04.014_bib17
  article-title: Strategies for development of Dengue virus inhibitors
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2009.12.011
– volume: 71
  start-page: 3466
  year: 1997
  ident: 10.1016/j.antiviral.2016.04.014_bib4
  article-title: RNA-protein interactions: involvement of NS3, NS5, and 3′ noncoding regions of Japanese encephalitis virus genomic RNA
  publication-title: J. Virol.
  doi: 10.1128/JVI.71.5.3466-3473.1997
– volume: 100
  start-page: 500
  year: 2013
  ident: 10.1016/j.antiviral.2016.04.014_bib14
  article-title: Ten years of dengue drug discovery: progress and prospects
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2013.09.013
– volume: 99
  start-page: 165
  year: 2013
  ident: 10.1016/j.antiviral.2016.04.014_bib29
  article-title: Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2013.05.011
– volume: 8
  start-page: e1002934
  year: 2012
  ident: 10.1016/j.antiviral.2016.04.014_bib1
  article-title: DENV inhibits type I IFN production in infected cells by cleaving human STING
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1002934
– volume: 123
  start-page: 5
  year: 2015
  ident: 10.1016/j.antiviral.2016.04.014_bib3
  article-title: Animal models for studying dengue pathogenesis and therapy
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2015.08.013
– volume: 58
  start-page: 110
  year: 2014
  ident: 10.1016/j.antiviral.2016.04.014_bib35
  article-title: A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01281-13
– volume: 5
  start-page: 37
  year: 1998
  ident: 10.1016/j.antiviral.2016.04.014_bib30
  article-title: Dopamine: pharmacologic and therapeutic aspects
  publication-title: Am. J. Ther.
  doi: 10.1097/00045391-199801000-00007
– volume: 290
  start-page: 2379
  year: 2015
  ident: 10.1016/j.antiviral.2016.04.014_bib27
  article-title: The C-terminal 50 amino acid residues of dengue NS3 protein are important for NS3-NS5 interaction and viral replication
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M114.607341
– volume: 96
  start-page: 305
  year: 2012
  ident: 10.1016/j.antiviral.2016.04.014_bib25
  article-title: Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2012.09.023
– volume: 92
  start-page: 2272
  year: 2011
  ident: 10.1016/j.antiviral.2016.04.014_bib18
  article-title: Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity
  publication-title: J. General Virol.
  doi: 10.1099/vir.0.031229-0
– volume: 27
  start-page: 493
  year: 1938
  ident: 10.1016/j.antiviral.2016.04.014_bib21
  article-title: A simple method of estimating fifty percent endpoints
  publication-title: Am. J. Hyg.
– volume: 67
  start-page: 209
  year: 2014
  ident: 10.1016/j.antiviral.2016.04.014_bib12
  article-title: Development of a novel Dengue-1 virus replicon system expressing secretory Gaussia luciferase for analysis of viral replication and discovery of antiviral drugs
  publication-title: Jpn. J. Infect. Dis.
  doi: 10.7883/yoken.67.209
– volume: 53
  start-page: 3226
  year: 2009
  ident: 10.1016/j.antiviral.2016.04.014_bib20
  article-title: Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00189-09
– volume: 87
  start-page: 2605
  year: 2006
  ident: 10.1016/j.antiviral.2016.04.014_bib28
  article-title: Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA
  publication-title: J. General Virol.
  doi: 10.1099/vir.0.81844-0
– volume: 841
  start-page: 135
  year: 1999
  ident: 10.1016/j.antiviral.2016.04.014_bib6
  article-title: Dopamine receptor-modulated [35S]GTPgammaS binding in striatum of 6-hydroxydopamine-lesioned rats
  publication-title: Brain Res.
  doi: 10.1016/S0006-8993(99)01812-0
– volume: 55
  start-page: 4072
  year: 2011
  ident: 10.1016/j.antiviral.2016.04.014_bib32
  article-title: A translation inhibitor that suppresses dengue virus in vitro and in vivo
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00620-11
– volume: 14
  start-page: 233
  year: 2007
  ident: 10.1016/j.antiviral.2016.04.014_bib10
  article-title: Phylogenetic analysis of dengue viruses isolated from imported dengue patients: possible aid for determining the countries where infections occurred
  publication-title: J. Travel Med.
  doi: 10.1111/j.1708-8305.2007.00130.x
– volume: 123
  start-page: 373
  year: 2012
  ident: 10.1016/j.antiviral.2016.04.014_bib5
  article-title: Molecular determinants of A2AR-D2R allosterism: role of the intracellular loop 3 of the D2R
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.2012.07956.x
– volume: 35
  start-page: 1943
  year: 1997
  ident: 10.1016/j.antiviral.2016.04.014_bib26
  article-title: A case of tick-borne encephalitis in Japan and isolation of the the virus
  publication-title: J. Clin. Microbiol.
  doi: 10.1128/JCM.35.8.1943-1947.1997
– volume: 107
  start-page: 17345
  year: 2010
  ident: 10.1016/j.antiviral.2016.04.014_bib9
  article-title: Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1010811107
– year: 2007
  ident: 10.1016/j.antiviral.2016.04.014_bib15
– volume: 366
  start-page: 1423
  year: 2012
  ident: 10.1016/j.antiviral.2016.04.014_bib23
  article-title: Dengue
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1110265
– volume: 366
  start-page: 293
  year: 1999
  ident: 10.1016/j.antiviral.2016.04.014_bib19
  article-title: Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/S0014-2999(98)00896-6
– volume: 379
  start-page: 73
  year: 2009
  ident: 10.1016/j.antiviral.2016.04.014_bib22
  article-title: The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease
  publication-title: Naunyn-Schmiedeberg’s Arch. Pharmacol.
  doi: 10.1007/s00210-008-0341-4
– volume: 44
  start-page: 649
  year: 1990
  ident: 10.1016/j.antiviral.2016.04.014_bib2
  article-title: Flavivirus genome organization, expression, and replication
  publication-title: Annu. Rev. Microbiol.
  doi: 10.1146/annurev.mi.44.100190.003245
– volume: 96
  start-page: 32
  year: 2012
  ident: 10.1016/j.antiviral.2016.04.014_bib33
  article-title: Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2012.07.008
– volume: 286
  start-page: 14362
  year: 2011
  ident: 10.1016/j.antiviral.2016.04.014_bib37
  article-title: Functional analysis of two cavities in flavivirus NS5 polymerase
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M110.214189
– volume: 91
  start-page: 11
  year: 2011
  ident: 10.1016/j.antiviral.2016.04.014_bib38
  article-title: Development and characterization of a stable luciferase dengue virus for high-throughput screening
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2011.05.001
– volume: 270
  start-page: 19100
  year: 1995
  ident: 10.1016/j.antiviral.2016.04.014_bib11
  article-title: Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.270.32.19100
– volume: 116
  start-page: 38
  year: 2006
  ident: 10.1016/j.antiviral.2016.04.014_bib24
  article-title: Nineteen nucleotides in the variable region of 3′ non-translated region are dispensable for the replication of dengue type 1 virus in vitro
  publication-title: Virus Res.
  doi: 10.1016/j.virusres.2005.08.015
– volume: 11
  start-page: 480
  year: 1998
  ident: 10.1016/j.antiviral.2016.04.014_bib8
  article-title: Dengue and dengue hemorrhagic fever
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/CMR.11.3.480
– volume: 89
  start-page: 8233
  year: 2015
  ident: 10.1016/j.antiviral.2016.04.014_bib31
  article-title: Discovery of dengue virus NS4B inhibitors
  publication-title: J. Virol.
  doi: 10.1128/JVI.00855-15
– volume: 48
  start-page: 1033
  year: 1999
  ident: 10.1016/j.antiviral.2016.04.014_bib36
  article-title: Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice
  publication-title: Metab. Clin. Exp.
  doi: 10.1016/S0026-0495(99)90202-0
– year: 2013
  ident: 10.1016/j.antiviral.2016.04.014_bib34
– volume: 78
  start-page: 1969
  year: 2012
  ident: 10.1016/j.antiviral.2016.04.014_bib7
  article-title: Role of LH in the progesterone increase during the bromocriptine-induced prolactin decrease in heifers
  publication-title: Theriogenology
  doi: 10.1016/j.theriogenology.2012.08.003
– volume: 118
  start-page: 148
  year: 2015
  ident: 10.1016/j.antiviral.2016.04.014_bib16
  article-title: The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2015.03.014
– volume: 89
  start-page: 3471
  year: 2015
  ident: 10.1016/j.antiviral.2016.04.014_bib39
  article-title: Mapping the Interactions between the NS4B and NS3 proteins of dengue virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.03454-14
– volume: 10
  year: 2011
  ident: 10.1016/j.antiviral.2016.04.014_bib13
  article-title: A physical interaction network of dengue virus and human proteins
  publication-title: Mol. Cell. Proteom. MCP
  doi: 10.1074/mcp.M111.012187
SSID ssj0006798
Score 2.409028
Snippet Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed vaccines or specific antiviral drugs against this...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 141
SubjectTerms Antiviral Agents - pharmacology
Bromocriptine - pharmacology
Dengue - drug therapy
Dengue virus
Dengue Virus - drug effects
Dengue Virus - physiology
Drug Resistance, Viral
Humans
Replicon - drug effects
Viral Plaque Assay
Virus Replication - drug effects
Title Novel antiviral activity of bromocriptine against dengue virus replication
URI https://www.ncbi.nlm.nih.gov/pubmed/27181378
https://www.proquest.com/docview/1808634425
Volume 131
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYlpaWX0qav7QsVegteZEuWtcdQGkIgOSWQnoxkS1lvGrukdiA99Ld39LB23aak6cUsZj3e9Yw_fTOaB0IfSZ3qIlcG3FStElYRmaicLhKqaKEXeSa5tMXJh0d8_4QdnOan64RMV13Sq3n148a6kv_RKpwDvdoq2TtoNgqFE_AZ9AtH0DAc_0nHR92VtqX-dgKELbS3RQpXIcdC2Tw7DwnAI-WZbIAI7gDKnA16B74-uP2CMWS3yVF3o7zQCShGjO0Adcd2h4tm2Vx2a7taNrVjoV-G8ybGbW14y0VXl017HeF_b1g1jd8yUkMvz-Vm4CHlMUk1xiI5T2jOpmAaMN3DYeqbWoWVNfW9Nf8AbR8_WM3j47IZd9x1oPUFptM22b8tXzGpcMxXW5VRUGkFlYSVxM46v5-BK2GxcP5znQZkd6F8_3f_ZyY5gDf-oimD-Ytb4ujJ8RP0OPgVeNcbyVN0T7fb6IGfNHq9jR4ehhyKZ-jAWQ2ON8Wj1eDO4InV4GA12FsNdlaDN6zmOTrZ-3z8aT8JEzWSivG0T4rMFERSwWB9rAB5gRwLRpVQTFLOa1pQszDMqEqQSmQVt96AMBIoHTXwTiv6Am21XatfIZybmi-kNkoCQVSFUDxXaUGYAvE6q8kM8fEplVVoN2-nnnwtb9HTDJF44TffceX2Sz6MaigBHe2Wl2x1N3wvUwEuO2WwMM3QS6-fKDQDWpbSQry--w3foEfrN-It2uovB_0OyGmv3jvr-gX82JKt
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+antiviral+activity+of+bromocriptine+against+dengue+virus+replication&rft.jtitle=Antiviral+research&rft.au=Kato%2C+Fumihiro&rft.au=Ishida%2C+Yuki&rft.au=Oishi%2C+Shinya&rft.au=Fujii%2C+Nobutaka&rft.date=2016-07-01&rft.issn=0166-3542&rft.volume=131&rft.spage=141&rft.epage=147&rft_id=info:doi/10.1016%2Fj.antiviral.2016.04.014&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_antiviral_2016_04_014
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0166-3542&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0166-3542&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0166-3542&client=summon